Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.
We report two cases of transfusion-dependent thalassemia treated by deferoxamine during the first trimesters of two successful pregnancies. The absence of any sign(s) of toxicity or teratogenicity is remarkable; despite the data from animal models, it seems that deferoxamine in humans is rather harmless for the fetus at the usually recommended doses.
Thalassemia Unit, Laikon Hospital, Athens, Greece.
E
E
Vaskaridou
K
K
Konstantopoulos
D
D
Kyriakou
D
D
Loukopoulos
D000014:Abnormalities, Drug-Induced; D000328:Adult; D001803:Blood Transfusion; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D013789:Thalassemia / Q000188:drug therapy* / Q000628:therapy; D017086:beta-Thalassemia / Q000188:drug therapy / Q000628:therapy
D003676:Deferoxamine